

Merck & Co., Inc.
UG2A-70
351 N. Sumneytown Pike
PO Box 1000
North Wales, PA 19454-2505



SUPPLY UPDATE: NASONEX® (mometasone furoate monohydrate) Nasal Spray, 50 mcg

October 5, 2015

Dear Pharmaceutical Purchaser:

On behalf of Merck Sharp & Dohme Corp. ("Merck"), a subsidiary of Merck & Co., Inc., I am writing to provide you with an update to the supply status of NASONEX.

The previous supply issue for NASONEX has been resolved and we anticipate that the product will be available to ship as of October 5, 2015. We apologize for any inconvenience this situation may have caused.

Product Information

How Supplied	Description	NDC NUMBER	Anticipated Availability Date*
NASONEX® (mometasone furoate monohydrate) 50 mcg Nasal Spray	Nasal Spray, 50 mcg† †calculated on the anhydrous basis	00085-1288-01	October 5, 2015

* This date is an estimate and may be subject to change.

All backorders will be filled on a first-in, first-out basis in accordance with Merck's standard practice. We anticipate that all backorders will be released.

If you have any additional questions, please contact your Merck Account Executive or call the Merck Order Management Center at 1-800-MERCK-RX (1-800-637-2579), Monday through Friday, 8:00 AM to 7:00 PM ET.

Sincerely,

A handwritten signature in black ink that reads "Paul J. Bader".

Paul J. Bader, R.Ph.
Director, Pharmacy & Distribution
Merck Sharp & Dohme Corp.